<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2021-08-08</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2544</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Novel Biomarkers of Endothelial Dysfunction in Cardiovascular Diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0444-9791</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдурахманов</surname><given-names>З. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdurakhmanov</surname><given-names>Z. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдурахманов Зуфар Мамурович </p><p>Бухара</p></bio><bio xml:lang="en"><p>Zufar M. Abdurakhmanov </p><p>Bukhara</p></bio><email xlink:type="simple">z_abdurakhmanov@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9173-2028</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Умаров</surname><given-names>Б. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Umarov</surname><given-names>B. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Умаров Бахтиер Ядгарович </p><p>Бухара</p></bio><bio xml:lang="en"><p>Bakhtiyor Y. Umarov </p><p>Bukhara</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8394-5453</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдурахманов</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdurakhmanov</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдурахманов Мамур Мустафаевич</p><p>Бухара</p></bio><bio xml:lang="en"><p>Mamur M. Abdurakhmanov </p><p>Bukhara</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Бухарский государственный медицинский институт</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Bukhara State Medical Institute</institution><country>Uzbekistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2021</year></pub-date><volume>17</volume><issue>4</issue><fpage>612</fpage><lpage>618</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Abdurakhmanov Z.M., Umarov B.Y., Abdurakhmanov M.M., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Абдурахманов З.М., Умаров Б.Я., Абдурахманов М.М.</copyright-holder><copyright-holder xml:lang="en">Abdurakhmanov Z.M., Umarov B.Y., Abdurakhmanov M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2544">https://www.rpcardio.online/jour/article/view/2544</self-uri><abstract><p>The review analyzes the role of assessing the state of the endothelium in the onset and progression of cardiovascular diseases, stratification of their risks, since endothelial dysfunction (ED) is a crucial predictor of this pathologies. In this regard, this paper presents the modern understanding of the methods for assessing ED, presents the advantages and disadvantages of various techniques. Despite the fact that flow-mediated dilation is widely used as a classical method for studying endothelial function, this technique depends on the physiological state of sensory nerves and calcium-activated potassium channels, cardiac output. This review focuses on new biomarkers for ED such as endothelial microparticles, endoglin and endocan, and discusses the relevance of the criteria for their use in clinical practice. Based on current scientific advances, the authors concluded that among these three newest biomarkers, today, endocan can be considered a more informative and reliable cellular marker of ED. Moreover, the authors have shown that when measured separately, many of the studied classical circulating biomarkers do not provide reliable information about the state of the endothelium, since the endothelial function has a complex physiological nature which therefore raises the question of the advisability of considering a combination of classical and new biomarkers for improving the assessment of the endothelial state.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре рассматривается роль оценки состояния эндотелия в возникновении и прогрессии сердечно-сосудистых заболеваний, стратификации их рисков, т.к. эндотелиальная дисфункция (ЭД) является важным предиктором подобных заболеваний. В настоящей работе изложено современное представление о способах оценки ЭД, представлены достоинства и недостатки различных методик. Несмотря на то, что потокзависимая вазодилатация широко используется как классический метод для исследования функции эндотелия, эта методика зависит от физиологического состояния сенсорных нервов и кальций-активируемых калиевых каналов, сердечного выброса. В данном обзоре внимание направлено на новые биомаркеры ЭД, эндотелиальные микрочастицы, эндоглин и эндокан, а также изложено обсуждение оснований их применения в клинической практике. Исходя из нынешних научных достижений, авторами сделан вывод, что среди из этих трех новейших биомаркеров эндокан в настоящее время может считаться более информативным и надежным клеточным маркером ЭД. Также авторами показано, что при измерении в отдельности многие из изученных классических циркулирующих биомаркеров не дают достоверную информацию о состоянии эндотелия, потому что функция эндотелия имеет сложный физиологический характер, что, следовательно, ставит вопрос о целесообразности комплексного рассмотрения комбинации классических и новых биомаркеров для улучшения оценки состояния эндотелия.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальная дисфункция</kwd><kwd>сердечно-сосудистое заболевание</kwd><kwd>эндотелиальная клетка</kwd><kwd>биомаркер</kwd><kwd>эндотелиальные микрочастицы</kwd><kwd>эндокан</kwd><kwd>эндоглин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>cardiovascular disease</kwd><kwd>endothelial cell</kwd><kwd>biomarker</kwd><kwd>endothelial microparticles</kwd><kwd>endoglin</kwd><kwd>endocan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174(12):1591-619. DOI:10.1111/bph.13517.</mixed-citation><mixed-citation xml:lang="en">Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174(12):1591-619. DOI:10.1111/bph.13517.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шабров А.В., Апресян А.Г., Добкес А.Л., и др. Современные методы оценки эндотелиальной дисфункции и возможности их применения в практической медицине. Рациональная Фармакотерапия в Кардиологии. 2016;12(6):733-42. DOI:10.20996/1819-6446-2016-12-6-733-742.</mixed-citation><mixed-citation xml:lang="en">Shabrov AV, Apresyan AG, Dobkes AL, et al. Current methods of endothelial dysfunction assessment and their possible use in the practical medicine. Rational Pharmacotherapy in Cardiology. 2016;12(6):733-42 (In Russ). DOI:10.20996/1819-6446-2016-12-6-733-742.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357418. DOI:10.1124/pr.115.011833.</mixed-citation><mixed-citation xml:lang="en">Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357418. DOI:10.1124/pr.115.011833.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850. DOI:10.3390/ijms22083850.</mixed-citation><mixed-citation xml:lang="en">Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850. DOI:10.3390/ijms22083850.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Munzel T, Gori T, Keaney JF, et al. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38):2555-64. DOI:10.1093/eurheartj/ehv305.</mixed-citation><mixed-citation xml:lang="en">Munzel T, Gori T, Keaney JF, et al. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38):2555-64. DOI:10.1093/eurheartj/ehv305.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI:10.1186/s12933-018-0763-3.</mixed-citation><mixed-citation xml:lang="en">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI:10.1186/s12933-018-0763-3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina (Kaunas). 2017;53(5):295-302. DOI:10.1016/j.medici.2017.08.003.</mixed-citation><mixed-citation xml:lang="en">Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina (Kaunas). 2017;53(5):295-302. DOI:10.1016/j.medici.2017.08.003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mordi I, Mordi N, Delles C, et al. Endothelial dysfunction in human essential hypertension. Journal of Hypertension. 2016;34(8):1464-72. DOI:10.1097/HJH.0000000000000965.</mixed-citation><mixed-citation xml:lang="en">Mordi I, Mordi N, Delles C, et al. Endothelial dysfunction in human essential hypertension. Journal of Hypertension.  2016;34(8):1464-72.  DOI:10.1097/HJH.0000000000000965.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gungor ZB, Sipahioglu N, Sonmez H, et al. Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females. Journal of Medical Biochemistry. 2017;36(1):62-72. DOI:10.1515/jomb-2016-0030.</mixed-citation><mixed-citation xml:lang="en">Gungor ZB, Sipahioglu N, Sonmez H, et al. Endothelial dysfunction markers in low cardiovascular risk individuals: comparison of males and females. Journal of Medical Biochemistry. 2017;36(1):62-72. DOI:10.1515/jomb-2016-0030.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Talavera-Adame D. Endothelium-derived essential signals involved in pancreas organogenesis. World Journal of Experimental Medicine. 2015;5(2):40. DOI:10.5493/wjem.v5.i2.40.</mixed-citation><mixed-citation xml:lang="en">Talavera-Adame D. Endothelium-derived essential signals involved in pancreas organogenesis. World Journal of Experimental Medicine. 2015;5(2):40. DOI:10.5493/wjem.v5.i2.40.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Castro-Ferreira R, Cardoso R, Leite-Moreira A, et al. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380-93. DOI:10.1016/j.avsg.2017.06.131.</mixed-citation><mixed-citation xml:lang="en">Castro-Ferreira R, Cardoso R, Leite-Moreira A, et al. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380-93. DOI:10.1016/j.avsg.2017.06.131.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandes DC, Araujo TSLS, Tanaka LY. Hemodynamic forces in the endothelium: from mechanotransduction to implications on development of atherosclerosis. In: Da Luz PL, Libby P, Chagas ACP, Laurindo FRM, eds. Endothelium and cardiovascular diseases: vascular biology and clinical syndromes. London, England: Academic Press; 2018:85-95. DOI:10.1177/0003319720946977.</mixed-citation><mixed-citation xml:lang="en">Fernandes DC, Araujo TSLS, Tanaka LY. Hemodynamic forces in the endothelium: from mechanotransduction to implications on development of atherosclerosis. In: Da Luz PL, Libby P, Chagas ACP, Laurindo FRM, eds. Endothelium and cardiovascular diseases: vascular biology and clinical syndromes. London, England: Academic Press; 2018:85-95. DOI:10.1177/0003319720946977.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tremblay JC, Grewal AS, Pyke KE. Examining the acute effects of retrograde versus low mean shear rate on flow-mediated dilation. J Appl Physiol. 2019;126(5):1335-42. DOI:10.1152/japplphysiol.01065.2018.</mixed-citation><mixed-citation xml:lang="en">Tremblay JC, Grewal AS, Pyke KE. Examining the acute effects of retrograde versus low mean shear rate on flow-mediated dilation. J Appl Physiol. 2019;126(5):1335-42. DOI:10.1152/japplphysiol.01065.2018.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Heo KS, Fujiwara K, Abe J. Shear stress and atherosclerosis. Mol Cells. 2014;37(6):435-40. DOI:10.14348/molcells.2014.0078.</mixed-citation><mixed-citation xml:lang="en">Heo KS, Fujiwara K, Abe J. Shear stress and atherosclerosis. Mol Cells. 2014;37(6):435-40. DOI:10.14348/molcells.2014.0078.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Walczak M, Suraj J, Kus K, et al. Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol Rep. 2015;67(4):771-7. DOI:10.1016/j.pharep.2015.06.008.</mixed-citation><mixed-citation xml:lang="en">Walczak M, Suraj J, Kus K, et al. Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol Rep. 2015;67(4):771-7. DOI:10.1016/j.pharep.2015.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Strisciuglio T, De Luca S, Capuano E, et al. Endothelial dysfunction: its clinical value and methods of assessment. Current Atherosclerosis Reports. 2014;16(6):417. DOI:10.1007/s11883-0140417-1.</mixed-citation><mixed-citation xml:lang="en">Strisciuglio T, De Luca S, Capuano E, et al. Endothelial dysfunction: its clinical value and methods of assessment. Current Atherosclerosis Reports. 2014;16(6):417. DOI:10.1007/s11883-0140417-1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243(1):339-43. DOI:10.1016/j.atherosclerosis.2015.09.030.</mixed-citation><mixed-citation xml:lang="en">Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243(1):339-43. DOI:10.1016/j.atherosclerosis.2015.09.030.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gifford JR, Richardson RS. CORP: ultrasound assessment of vascular function with the passive leg movement technique. J Appl Physiol. 2017;123(6):1708-20. DOI:10.1152/japplphysiol.00557.2017.</mixed-citation><mixed-citation xml:lang="en">Gifford JR, Richardson RS. CORP: ultrasound assessment of vascular function with the passive leg movement technique. J Appl Physiol. 2017;123(6):1708-20. DOI:10.1152/japplphysiol.00557.2017.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wang XS, Yang W, Luo T, et al. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124-7. DOI:10.1089/gtmb.2014.0274.</mixed-citation><mixed-citation xml:lang="en">Wang XS, Yang W, Luo T, et al. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124-7. DOI:10.1089/gtmb.2014.0274.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt DE, Manca M, Hoefer IE. Circulating endothelial cells in coronary artery disease and acute coronary syndrome. Trends Cardiovasc Med. 2015;25(7):578-87. DOI:10.1016/j.tcm.2015.01.013..</mixed-citation><mixed-citation xml:lang="en">Schmidt DE, Manca M, Hoefer IE. Circulating endothelial cells in coronary artery disease and acute coronary syndrome. Trends Cardiovasc Med. 2015;25(7):578-87. DOI:10.1016/j.tcm.2015.01.013..</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Santilli F, Marchisio M, Lanuti P, et al. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016;116(2):220-34. DOI:10.1160/TH16-03-0176.</mixed-citation><mixed-citation xml:lang="en">Santilli F, Marchisio M, Lanuti P, et al. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016;116(2):220-34. DOI:10.1160/TH16-03-0176.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Alexandru N, Badila E, Weiss E, et al. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472(1):1-10. DOI:10.1016/j.bbrc.2016.02.038.</mixed-citation><mixed-citation xml:lang="en">Alexandru N, Badila E, Weiss E, et al. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472(1):1-10. DOI:10.1016/j.bbrc.2016.02.038.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Parker B, Al-Husain A, Pemberton P, et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis. 2014;73(6):1144-50. DOI:10.1136/annrheumdis-2012-203028.</mixed-citation><mixed-citation xml:lang="en">Parker B, Al-Husain A, Pemberton P, et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis. 2014;73(6):1144-50. DOI:10.1136/annrheumdis-2012-203028.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Song R, Chou YI, Kong J, et al. Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. Biomarkers. 2015; 20(67):429-35. DOI:10.3109/1354750X.2015.1094140.</mixed-citation><mixed-citation xml:lang="en">Song R, Chou YI, Kong J, et al. Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. Biomarkers. 2015; 20(67):429-35. DOI:10.3109/1354750X.2015.1094140.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Goumans MJ, Ten Dijke P. TGF-beta signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210. DOI:10.1101/cshperspect.a022210.</mixed-citation><mixed-citation xml:lang="en">Goumans MJ, Ten Dijke P. TGF-beta signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210. DOI:10.1101/cshperspect.a022210.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jang YS, Choi IH. Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw. 2014;14(5):237-40. DOI:10.4110/in.2014.14.5.237.</mixed-citation><mixed-citation xml:lang="en">Jang YS, Choi IH. Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw. 2014;14(5):237-40. DOI:10.4110/in.2014.14.5.237.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jezkova K, Rathouska J, Nemeckova I, et al. High levels of soluble endoglin induce a proinflammatory and oxidativestress phenotype associated with preserved no-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res. 2016;53(3-4):149-62. DOI:10.1159/000448996.</mixed-citation><mixed-citation xml:lang="en">Jezkova K, Rathouska J, Nemeckova I, et al. High levels of soluble endoglin induce a proinflammatory and oxidativestress phenotype associated with preserved no-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res. 2016;53(3-4):149-62. DOI:10.1159/000448996.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Vitverova B, Blazickova K, Najmanova I, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25. DOI:10.1016/j.atherosclerosis.2018.02.008.</mixed-citation><mixed-citation xml:lang="en">Vitverova B, Blazickova K, Najmanova I, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25. DOI:10.1016/j.atherosclerosis.2018.02.008.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Varejckova M, Gallardo-Vara E, Vicen M, et al. Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 2017;175:52-60. DOI:10.1016/j.lfs.2017.03.014.</mixed-citation><mixed-citation xml:lang="en">Varejckova M, Gallardo-Vara E, Vicen M, et al. Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 2017;175:52-60. DOI:10.1016/j.lfs.2017.03.014.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Emeksiz HC, Bideci A, Damar C, et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. J Clin Res Pediatr Endocrinol. 2016;8(3):313-20. DOI:10.4274/jcrpe.2906.</mixed-citation><mixed-citation xml:lang="en">Emeksiz HC, Bideci A, Damar C, et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. J Clin Res Pediatr Endocrinol. 2016;8(3):313-20. DOI:10.4274/jcrpe.2906.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gerrits T, Zandbergen M, Wolterbeek R, et al. Endoglin promotes myofibroblast differentiation and extracellular matrix production in diabetic nephropathy. Int J Mol Sci. 2020;21(20):7713. DOI:10.3390/ijms21207713.</mixed-citation><mixed-citation xml:lang="en">Gerrits T, Zandbergen M, Wolterbeek R, et al. Endoglin promotes myofibroblast differentiation and extracellular matrix production in diabetic nephropathy. Int J Mol Sci. 2020;21(20):7713. DOI:10.3390/ijms21207713.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ikemoto T, Hojo Y, Kondo H, et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27(4):344-51. DOI:10.1007/s00380-011-0163-z.</mixed-citation><mixed-citation xml:lang="en">Ikemoto T, Hojo Y, Kondo H, et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27(4):344-51. DOI:10.1007/s00380-011-0163-z.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Redgrave R.E, Tual-Chalot S, Davison B.J, et el. Cardiosphere-derived cells require endoglin for paracrine-mediated angiogenesis. Stem cell reports. 2017;8(5):1287-98. DOI:10.1016/j.stemcr.2017.04.015.</mixed-citation><mixed-citation xml:lang="en">Redgrave R.E, Tual-Chalot S, Davison B.J, et el. Cardiosphere-derived cells require endoglin for paracrine-mediated angiogenesis. Stem cell reports. 2017;8(5):1287-98. DOI:10.1016/j.stemcr.2017.04.015.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Canpolat U, Kocyigit D, Yildirim A. Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point? Angiology. 2020;71(5):477. DOI:10.1177/0003319716654627.</mixed-citation><mixed-citation xml:lang="en">Canpolat U, Kocyigit D, Yildirim A. Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point? Angiology. 2020;71(5):477. DOI:10.1177/0003319716654627.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581-90. DOI:10.1161/CIRCRESAHA.115.304718.</mixed-citation><mixed-citation xml:lang="en">Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581-90. DOI:10.1161/CIRCRESAHA.115.304718.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lee W, Ku S.K, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620-30. DOI:10.1002/jcp.24485.</mixed-citation><mixed-citation xml:lang="en">Lee W, Ku S.K, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620-30. DOI:10.1002/jcp.24485.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H, Zhang H, Li K, et al. ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234(2):1512-21. DOI:10.1002/jcp.27016.</mixed-citation><mixed-citation xml:lang="en">Sun H, Zhang H, Li K, et al. ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234(2):1512-21. DOI:10.1002/jcp.27016.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Icli A, Cure E, Cure MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749-55. DOI:10.1177/0003319715616240.</mixed-citation><mixed-citation xml:lang="en">Icli A, Cure E, Cure MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749-55. DOI:10.1177/0003319715616240.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. DOI:10.1186/s13054-018-2222-7.</mixed-citation><mixed-citation xml:lang="en">De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. DOI:10.1186/s13054-018-2222-7.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Hsiao SY, Kung CT, Tsai NW, et al. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275-80. DOI:10.1016/j.cca.2018.05.007.</mixed-citation><mixed-citation xml:lang="en">Hsiao SY, Kung CT, Tsai NW, et al. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275-80. DOI:10.1016/j.cca.2018.05.007.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gungor A, Palabiyik S.S, Bayraktutan Z, et al. Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidism. Endocr Res. 2016;41(4):275-80. DOI:10.3109/07435800.2015.1135443.</mixed-citation><mixed-citation xml:lang="en">Gungor A, Palabiyik S.S, Bayraktutan Z, et al. Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidism. Endocr Res. 2016;41(4):275-80. DOI:10.3109/07435800.2015.1135443.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Cimen T, Efe TH, Akyel A, et al. Human endothelial cellspecific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67(3):846-53. DOI:10.1177/0003319715625827.</mixed-citation><mixed-citation xml:lang="en">Cimen T, Efe TH, Akyel A, et al. Human endothelial cellspecific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67(3):846-53. DOI:10.1177/0003319715625827.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Kundi H, Balun A, Cicekcioglu H, et al. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932.</mixed-citation><mixed-citation xml:lang="en">Kundi H, Balun A, Cicekcioglu H, et al. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan concentration in patients with primary hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158.</mixed-citation><mixed-citation xml:lang="en">Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan concentration in patients with primary hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Lv Y, Zhang Y, Shi W, et al. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004.</mixed-citation><mixed-citation xml:lang="en">Lv Y, Zhang Y, Shi W, et al. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Balamir I, Ates I, Topcuoglu C, et al. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69(7):609-16. DOI:10.1177/0003319717740781.</mixed-citation><mixed-citation xml:lang="en">Balamir I, Ates I, Topcuoglu C, et al. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69(7):609-16. DOI:10.1177/0003319717740781.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Altintas N, Mutlu LC, Akkoyun D.C, et al. Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology. 2016;67(4):364-74. DOI:10.1177/0003319715590558.</mixed-citation><mixed-citation xml:lang="en">Altintas N, Mutlu LC, Akkoyun D.C, et al. Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology. 2016;67(4):364-74. DOI:10.1177/0003319715590558.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213-20. DOI:10.1038/ki.2014.227.</mixed-citation><mixed-citation xml:lang="en">Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213-20. DOI:10.1038/ki.2014.227.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Med (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407.</mixed-citation><mixed-citation xml:lang="en">Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Med (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
